Antigens, Protozoan

• 

  Subject Areas on Research

  • A deep sequencing approach to estimate Plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity. 
  • A longitudinal cohort study of malaria exposure and changing serostatus in a malaria endemic area of rural Tanzania. 
  • A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples. 
  • Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome. 
  • Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. 
  • Antibodies to Trichomonas vaginalis surface glycolipid. 
  • Antigen-specific B memory cell responses to Plasmodium falciparum malaria antigens and Schistosoma haematobium antigens in co-infected Malian children. 
  • Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum. 
  • Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. 
  • Complexity of the msp2 locus and the severity of childhood malaria, in south-western Nigeria. 
  • Designing malaria vaccines to circumvent antigen variability. 
  • Diagnosis of Giardia lamblia infections by detection of parasite-specific antigens. 
  • Diagnosis of canine visceral leishmaniasis with a dot-enzyme-linked immunosorbent assay. 
  • Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravid, malaria-exposed Malian women. 
  • Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. 
  • Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. 
  • Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. 
  • Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. 
  • Human antibody response to Anopheles gambiae saliva: an immuno-epidemiological biomarker to evaluate the efficacy of insecticide-treated nets in malaria vector control. 
  • IRGM3 contributes to immunopathology and is required for differentiation of antigen-specific effector CD8+ T cells in experimental cerebral malaria. 
  • Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. 
  • Increased risk of low birth weight in women with placental malaria associated with P. falciparum VAR2CSA clade. 
  • Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. 
  • Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. 
  • Mapping hypoendemic, seasonal malaria in rural Bandarban, Bangladesh: a prospective surveillance. 
  • Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. 
  • Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. 
  • Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. 
  • Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. 
  • Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral leishmaniasis. 
  • Plasma Plasmodium falciparum histidine-rich protein-2 concentrations are associated with malaria severity and mortality in Tanzanian children. 
  • Potentiation of cell-mediated immune responses directed against P. falciparum sporozoite peptide vaccine by immunomodulators. 
  • Prevalence of human African trypanosomiasis in the Democratic Republic of the Congo. 
  • Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. 
  • Quantification of Plasmodium falciparum histidine-rich protein-2 in cerebrospinal spinal fluid from cerebral malaria patients. 
  • Rapid Diagnostic Test Performance Assessed Using Latent Class Analysis for the Diagnosis of Plasmodium falciparum Placental Malaria. 
  • Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. 
  • Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. 
  • Seroreactivity to Plasmodium falciparum erythrocyte membrane protein 1 intracellular domain in malaria-exposed children and adults. 
  • Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria. 
  • Strain theory of malaria: the first 50 years. 
  • Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine. 
  • Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. 
  • The diagnosis of Plasmodium falciparum infection using a new antigen detection system. 
  • Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. 
  • [Evaluation of a rapid test using recombinant k39 antigen in the diagnosis of visceral leishmaniasis in Brazil ].